

Table S1: Stability data of 5-AIQ in human plasma (n = 5).

Stability	Nominal concentration (ng/mL) (n=6)	Precision (RSD, %)	Bias (RE, %)
Short-term (8 h)	50	1.7	-2.6
	500	3.3	7.4
Freeze thaw (3 cycle)	50	3.8	-4.1
	500	4.2	-13.5
Autosampler (24 h at 15°C)	50	10.5	5.7
	500	7.2	7.6
2 month at -70°C	50	7.9	-10.1
	500	3.6	-8.3

Table S2: ADME properties of 5-AIQ screened by SwissADME software.

Physicochemical Properties	
Formula	C ₉ H ₈ N ₂
Molecular weight	144.17 g/mol
Num. heavy atoms	11
Num. arom. heavy atoms	10
Fraction Csp ³	0.00
Num. rotatable bonds	0
Num. H-bond acceptors	1
Num. H-bond donors	1
Molar Refractivity	46.15
TPSA	38.91 Å ²
Lipophilicity	
Log <i>P</i> _{o/w} (iLOGP)	1.27
Log <i>P</i> _{o/w} (XLOGP3)	1.42
Log <i>P</i> _{o/w} (WLOGP)	1.82
Log <i>P</i> _{o/w} (MLOGP)	0.92
Log <i>P</i> _{o/w} (SILICOS-IT)	1.77
Consensus Log <i>P</i> _{o/w}	1.44
Water Solubility	
Log <i>S</i> (ESOL)	-2.30
Solubility	7.21e-01 mg/ml ; 5.00e-03 mol/l
Class	Soluble
Log <i>S</i> (Ali)	-1.84
Solubility	2.08e+00 mg/ml ; 1.44e-02 mol/l
Class	Very soluble
Log <i>S</i> (SILICOS-IT)	-3.32
Solubility	6.93e-02 mg/ml ; 4.81e-04 mol/l
Class	Soluble
Pharmacokinetics	
GI absorption	High

BBB permeant	Yes
P-gp substrate	No
CYP1A2 inhibitor	Yes
CYP2C19 inhibitor	No
CYP2C9 inhibitor	No
CYP2D6 inhibitor	No
CYP3A4 inhibitor	No
Log K_p (skin permeation)	-6.17 cm/s
Druglikeness	
Lipinski	Yes; 0 violation
Ghose	No; 2 violations: MW<160, #atoms<20
Veber	Yes
Egan	Yes
Muegge	No; 1 violation: MW<200
Bioavailability Score	0.55
Medicinal Chemistry	
PAINS	0 alert
Brenk	1 alert: aniline
Leadlikeness	No; 1 violation: MW<250
Synthetic accessibility	1.00